

- **Full Name:** Hee Kyung Kim
 - **Current Position & Affiliation:** Clinical Associate Professor, Chungbuk National University Hospital
 - **Country:** Republic of Korea
-

• Educational Background:

- 2011 M.D. / College of Medicine, Sungkyunkwan University
- 2016 M.S. / College of Medicine, Sungkyunkwan University
- 2018 Ph.D. / College of Medicine, Sungkyunkwan University

• Professional Experience:

- 2012-2016 Residency, Internal Medicine, Samsung Medical Center, Seoul
- 2016-2018 Clinical Fellow, Division of Hematology and Oncology, Department of Internal Medicine, Samsung Medical Center, Seoul
- 2018-2023 Clinical Assistant Professor, Division of Hematology-Oncology, Chungbuk National University Hospital, Cheongju
- 2023-present Clinical Associate Professor, Division of Hematology-Oncology, Chungbuk National University Hospital, Cheongju

• Professional Organizations:

- Korean Association of Internal Medicine
- Korean Society of Medical Oncology (KSMO)
- American Society of Clinical Oncology (ASCO)
- American Association of Cancer Research (AACR) – Active membership
- European Society of Medical Oncology (ESMO)

• Main Scientific Publications:

1. Beom SH, Kim JG, Baik SH, Shin SH, Park I, Park YS, Lee MA, Lee S, Jeon SY, Han SW, Kang MH, Oh J, Kim JS, Kim JY, Ahn MS, Zang DY, Bae BN, Jo HJ, **Kim HK**, Kim JH, Yoon JA, Kim DH. Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. *J Cancer Res Clin Oncol.* 2023 Mar;149(3):1131-1143.
2. Lee J, Koh J, **Kim HK**, Hong S, Kim K, Park S, Jung HA, Sun JM, Lee S-H, Ahn JS, Park K, Ahn MJ. Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial. *J Thoracic Oncol.* 2022 Jul;17(7):900-908.
3. **Kim HK**, Yang Y, Byeon S, Jeong Y, Kwon J, Lee KH, Son SM, Han HS. E-Cadherin and Angiopoietin-2 as Potential Biomarkers for Colorectal Cancer With Peritoneal Carcinomatosis. *Anticancer Res.* 2021 Sep;41(9):4497-4504.
4. **Kim HK**, Lee HS, Heo MH, Kim JY, Ahn JS, Im YH, Lee JI, Park YH. Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype. *Clin Breast Cancer.* 2021 Aug;21(4):e402-e414.
5. **Kim HK**, Kang W, Sinn DH, Lee JH, Kim WS, Kim SJ. Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. *Korean J Intern Med.* 2020 Jan;35(1):194-204.
6. **Kim HK**, Lee I, Kim ST, Lee J, Kim KM, Park JO, Kang WK. RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. *Sci Rep.* 2019 Dec 19;9(1):19439.

7. **Kim HK**, Lee I, Bang H, Kim HC, Lee WY, Yun SH, Lee J, Lee SJ, Park YS, Kim KM, Kang WK. MCT4 Expression is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. *Mol Cancer Ther.* 2018 Apr;17(4):838-848.
8. **Kim HK**, Ahn MJ. Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer. *Expert Opinion on Orphan Drugs.* 2018. Mar: 253-258